Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cancer vaccine boosts immunotherapy in advanced lung and Head/Neck tumors

NCT ID NCT02955290

First seen Nov 10, 2025 · Last updated May 22, 2026 · Updated 22 times

Summary

This study tests a vaccine called CIMAvax combined with immunotherapy drugs (nivolumab or pembrolizumab) in people with advanced non-small cell lung cancer or head/neck cancer that has spread. The goal is to find the best dose and see if the combination helps control tumor growth and extends survival. About 51 adults with these cancers are taking part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG NON-SMALL CELL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Good Samaritan Hospital

    West Islip, New York, 11795, United States

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center

    Indianapolis, Indiana, 46202, United States

  • Roswell Park Cancer Institute

    Buffalo, New York, 14263, United States

  • St. Francis Hospital

    Roslyn, New York, 11576, United States

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio, 44106, United States

Conditions

Explore the condition pages connected to this study.